Clinical characteristics in patients who received triple-combo therapy in comparison with those who received dual-combo therapy or monotherapy included a higher prevalence of CADM, fever, skin ulcerations, lower consolidation/ground-glass attenuation and random ground-glass attenuation on chest high-resolution computed tomography, and requirement of supplemental oxygen; higher levels of CRP and ferritin; lower levels of CK and SP-D; and a higher proportion of anti-MDA5 antibody and lower proportion of anti-ARS antibody. This evidence concerns the gene SFTPD and clinically amyopathic dermatomyositis.